Guidelines for the use of Pegfilgrastim (Neulasta®)

Appropriate regimens for pegfilgrastim support:

- **DHAP** (doxorubicin, high-dose cytarabine)
- **ESHAP** (etoposide, cisplatin, high-dose cytarabine)
- Induction / consolidation regimens for ALL (acute lymphoblastic leukemia)
- High-dose cyclophosphamide (> 2 grams/m²)
- Cyclophosphamide / etoposide combinations
- Previous regimen (e.g., with carboplatinum / taxol) for non-myeloid malignancy that has resulted in prolonged neutropenia (> 10 days) -- including patients with gynecological or lung cancer
- Patients on randomized studies for pegfilgrastim

Other possible considerations detailed on the CareLink authorization request form for pegfilgrastim:

- Psychosocial situations that make daily filgrastim impossible or impractical; i.e., long distance from hospital or lack of transportation.

Inappropriate regimens (unless specifically on an IRB-approved study) for pegfilgrastim support:

- Any patient with AML (Acute Myelodysplastic Leukemia)
  OR
- Any patient with MDS (Myledysplastic Syndrome)

All CareLink patients will require prior authorization (call 358-3224) and must be evaluated for the manufacturer’s Medication Assistance Program.

Natalie S. Callandar, M.D.
Associate Professor of Medicine

Approved by the Pharmacy & Therapeutics Committee May 2004